We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
-6.18%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$20.6B
AUM Growth
-$2.22B
Cap. Flow
+$62.6M
Cap. Flow %
0.3%
Top 10 Hldgs %
83.49%
Holding
126
New
5
Increased
17
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
TRDA icon
Entrada Therapeutics
TRDA
+$114M
2
INCY icon
Incyte
INCY
+$108M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$46.7M
4
TSVT
2seventy bio
TSVT
+$26M
5
TVTX icon
Travere Therapeutics
TVTX
+$17.7M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$66.1M
2
FLGT icon
Fulgent Genetics
FLGT
+$17.5M
3
BLUE
bluebird bio
BLUE
+$16M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$12.9M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.22%
2 Miscellaneous 0.78%
3 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNGX icon
76
Tango Therapeutics
TNGX
$4.01B
$8.21M 0.04%
750,000
– –
KYNB
77
Kyntra Bio
KYNB
$32.3M
$8.18M 0.04%
+23,206
New +$7.23M
EWTX icon
78
Edgewise Therapeutics
EWTX
$4.82B
$7.64M 0.04%
500,000
– –
CBAY
79
DELISTED
Cymabay Therapeutics
CBAY
$7.34M 0.04%
2,170,464
– –
MGNX icon
80
MacroGenics
MGNX
$255M
$7.1M 0.03%
442,579
– –
ITOS
81
DELISTED
iTeos Therapeutics
ITOS
$7M 0.03%
150,346
– –
NVAX icon
82
Novavax
NVAX
$1.55B
$6.89M 0.03%
48,168
-60,588
-56% -$10.4M
ALLK
83
DELISTED
Allakos
ALLK
$6.88M 0.03%
703,050
– –
TCRX icon
84
TScan Therapeutics
TCRX
$21.7M
$6.41M 0.03%
1,425,000
– –
RETA
85
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.91M 0.03%
223,976
– –
RVMD icon
86
Revolution Medicines
RVMD
$43.7B
$5.59M 0.03%
222,222
– –
HRMY icon
87
Harmony Biosciences
HRMY
$2.42B
$5.27M 0.03%
123,600
– –
NGM
88
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$5.17M 0.03%
291,801
– –
ALEC icon
89
Alector
ALEC
$239M
$4.94M 0.02%
239,228
– –
ATYR
90
aTyr Pharma
ATYR
$38.1M
$4.67M 0.02%
625,000
– –
KURA icon
91
Kura Oncology
KURA
$1.01B
$4.26M 0.02%
304,158
– –
DNLI icon
92
Denali Therapeutics
DNLI
$3.37B
$3.96M 0.02%
88,738
– –
BMEA icon
93
Biomea Fusion
BMEA
$126M
$3.91M 0.02%
524,617
– –
TCRR
94
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$3.51M 0.02%
753,064
+576,603
+327% +$3.6M
GTH
95
DELISTED
Genetron Holdings Limited ADS
GTH
$2.78M 0.01%
151,769
– –
CABA icon
96
Cabaletta Bio
CABA
$463M
$2.51M 0.01%
662,063
– –
AKRO
97
DELISTED
Akero Therapeutics
AKRO
$2.5M 0.01%
118,378
– –
VINC
98
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$2.46M 0.01%
12,069
– –
ALBO
99
DELISTED
Albireo Pharma Inc
ALBO
$2.43M 0.01%
104,521
-307,945
-75% -$8.19M
SNDX icon
100
Syndax Pharmaceuticals
SNDX
$1.62B
$2.42M 0.01%
110,729
– –
1 2 3
4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Baker Bros. Advisors's Q4 2021 Portfolio in Review

As of Q4 2021, Baker Bros. Advisors held 126 positions worth $20.6B, down 9.7% from $22.8B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors's Q4 2021 filing shows 5 new, 17 increased, 8 reduced and 5 closed positions. Its largest new stake was Entrada Therapeutics: 4,704,419 shares worth $80.5M. The largest sale was Seagen Inc. Common Stock, an estimated $66.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous and Financials.

  • Baker Bros. Advisors's largest Q4 2021 buy was Entrada Therapeutics: 4,704,419 shares worth $80.5M.
  • Baker Bros. Advisors added most to Incyte in Q4 2021, an estimated $108M increase.
  • Baker Bros. Advisors's biggest Q4 2021 reduction was Seagen Inc. Common Stock, cutting an estimated $66.1M.
  • Baker Bros. Advisors fully exited Mirum Pharmaceuticals in Q4 2021, selling an estimated $12.9M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $20.6B portfolio in Q4 2021.
  • Baker Bros. Advisors opened 5 new positions and closed 5 in Q4 2021.
  • Baker Bros. Advisors's portfolio value fell 9.7% quarter-over-quarter to $20.6B.

Based on Baker Bros. Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.